Motilal Oswal's Bold Stock Picks: TCS, SBI, Biocon & More Revealed! Where Will Your Next Investment Soar?

Motilal Oswal Financial Services Research has released its latest list of stock recommendations, identifying key opportunities across the Indian equity market. The report highlights companies poised for significant growth, driven by strong strategic initiatives, market leadership, and favorable sector tailwinds. Investors are presented with carefully selected picks spanning large, mid, and small-cap segments.

This strategic selection aims to provide a roadmap for potential investment gains, with the research firm detailing the underlying rationale for each recommendation. The focus areas include cutting-edge technology, essential banking services, pharmaceutical innovation, industrial strength, defense capabilities, and sophisticated wealth management solutions.

Large-Cap Focus: TCS and SBI

Tata Consultancy Services (TCS) has been identified for its ambitious vision to become the world's foremost AI-led technology services company. This objective is supported by an AI-first operating model, redefined AI services, and a talent strategy focused on AI fluency. The company is actively building its AI ecosystem through partnerships, mergers, and acquisitions.
TCS has already disclosed an annualised AI services revenue of $1.5 billion, demonstrating a robust 16 percent quarter-on-quarter growth. Its strategy involves ecosystem-led scaling and an AI-first data center approach, leveraging Tier-3+ facilities built to NVIDIA specifications. The firm anticipates 4.5 percent and 7.2 percent constant currency growth in FY27 and FY28, respectively, with strong Ebit margins and valuations trading at a discount to historical averages.
State Bank of India (SBI) continues to exhibit market resilience and leadership, capitalizing on its extensive customer base and structural advantages. In the second quarter of FY26, the bank reported a Profit After Tax (PAT) of ₹20,160 crore, marking a 10 percent year-on-year increase. This performance was bolstered by strong Net Interest Income (NII) growth and exceptional gains from the Yes Bank stake sale.
Core PAT stood at ₹16,700 crore, aligning with expectations, while Net Interest Margins (NIMs) expanded by 7 basis points sequentially to 2.97 percent. Asset quality improved, with Gross Non-Performing Assets (GNPA) and Net Non-Performing Assets (NNPA) reported at 1.73 percent and 0.42 percent, respectively. Management projects loan growth between 12-14 percent for FY26 and NIMs exceeding 3 percent, supported by ongoing structural initiatives and a strong corporate pipeline.

Mid-Cap Movers: Biocon and Dalmia Bharat

Biocon's complete consolidation of Biocon Biologics is expected to eliminate the holding-company discount and grant full strategic control over its biologics, generics, and Contract Development and Manufacturing Organisation (CDMO) segments. The integrated platform is set for enhanced scaling, driven by upcoming product launches, including insulin aspart, expansion in generics, and operating leverage from Syngene.
The acquisition of the remaining 23.3 percent stake is funded through a share swap and bridge financing alongside a Qualified Institutional Placement (QIP). While equity issuance may lead to near-term earnings per share (EPS) dilution, the business prospects remain encouraging due to promising product launches, a scaling generics business, and Syngene's growth trajectory.
Dalmia Bharat demonstrated operational strength in its recent quarterly performance, despite transitional headwinds such as muted demand in the first half due to heavy rainfall and GST-related disruptions. Rising petcoke prices and INR depreciation pose near-term cost pressures. However, Earnings Before Interest, Tax, Depreciation, and Amortisation (Ebitda) grew approximately 60 percent year-on-year, with margins expanding over six percentage points to 20 percent.
Profitability surged on a lower base, aided by higher other income and a favorable tax rate. Management anticipates demand recovery in the second half as the GST rate benefit has been passed on. Ongoing capacity expansions at Belgaum and Kadapa are on schedule, reinforcing medium-term growth visibility. Motilal Oswal maintains a 'Buy' rating, citing strong execution, margin recovery, and disciplined cost management.

Small-Cap Opportunities: Astra Microwave Products and Nuvama Wealth

Astra Microwave Products (AMPL) is transitioning from a subsystem supplier to a full system solutions provider in defense electronics. The company is targeting significant opportunities in AESA and Uttam radars, meteorological projects, Navy repeat orders, and counter-drone systems. As of September 2025, AMPL held an order book of ₹2,200 crore.
The firm expects an 18 percent revenue CAGR and a 23 percent PAT CAGR over FY25-28, with Ebitda margins nearing 26 percent. Motilal Oswal views AMPL as a compelling long-term investment in defense electronics, with revenue growth projected to accelerate between FY27-30 as larger orders are awarded by the Ministry of Defence and defense Public Sector Undertakings.
Nuvama Wealth continues to solidify its position in the wealth and private client segments, driven by improved client retention and healthy inflows. In Q2FY26, operating revenue grew 4 percent year-on-year to ₹770 crore, primarily from the Wealth and Private businesses, offsetting weaknesses in AMC and Capital Markets. PAT stood at ₹250 crore, remaining flat year-on-year but exceeding estimates by 9 percent, supported by effective cost control.
Management has maintained its PAT growth guidance of 20-25 percent for the fiscal year, anticipating a recovery in the asset services segment and sustained momentum in wealth flows. Operating efficiency is expected to improve, with opex growth guided between 8-10 percent for FY26. Motilal Oswal forecasts Nuvama Wealth to deliver a 15 percent revenue CAGR and a 16 percent PAT CAGR over the FY25-28 period.

Impact

The recommendations from Motilal Oswal Financial Services Research are highly significant for Indian stock market investors, offering potential high-growth opportunities.
The focus on companies leveraging AI, strong banking fundamentals, innovative pharmaceuticals, essential industrial materials, advanced defense technology, and robust wealth management services signals key trends and growth sectors within the Indian economy.
These picks could lead to increased investor interest and potential price appreciation in the targeted stocks, influencing market sentiment towards these specific companies and their respective sectors.
The explicit mention of target prices and 'Buy' ratings suggests a bullish outlook from the research firm on these selected entities.

Impact Rating: 9/10

Difficult Terms Explained

AI-led technology services: Refers to technology services where Artificial Intelligence plays a central role in delivery or function.
AI-first operating model: A business approach where AI is integrated into the core operations and decision-making processes from the outset.
AI-fluent talent strategy: A plan to develop or acquire a workforce proficient in understanding and utilizing AI technologies.
AI ecosystem: The network of partners, technologies, and resources that support the development and deployment of AI.
Annualised AI services revenue: The total revenue generated from AI services, projected or calculated for a full year.
Quarter-on-quarter (Q-o-Q): A comparison of a metric from one fiscal quarter to the next.
Build-partner-acquire strategy: A corporate strategy involving developing internal capabilities, collaborating with others, and acquiring other companies to achieve goals.
AI stack: The different layers of technology and software required to implement AI solutions.
Ecosystem-led scaling: Growing a business by leveraging a network of external partners and collaborators.
AI-first data center: A data center specifically designed and optimized for AI workloads and infrastructure.
Tier-3+ facilities: A classification for data centers indicating high levels of redundancy, power, and cooling, ensuring continuous operation.
NVIDIA specifications: Standards and requirements set by NVIDIA, a leader in graphics processing units (GPUs) often used for AI computing.
Industry-leading margins: Profit margins that are higher than the average or best achieved by competitors in the same industry.
Superior returns: Investment returns that are significantly better than those typically achieved in the market or by peers.
Year-on-year (Y-o-Y): A comparison of a metric from one year to the same period in the previous year.
Constant currency (CC) growth: Revenue growth calculated without the impact of foreign exchange rate fluctuations, providing a clearer picture of underlying business performance.
Earnings Before Interest and Tax (Ebit) margins: A profitability ratio showing profit as a percentage of revenue before deducting interest and taxes.
Valuations: The process of determining the current worth of an asset or company.
Discount to historical averages: When current valuations are lower than the company's typical valuation levels in the past.
Resilience: The ability of a company or asset to withstand or recover quickly from difficult financial or market conditions.
Market leadership: Holding a dominant position in terms of market share or influence within an industry.
Structural advantages: Inherent benefits or characteristics that provide a company with a long-term competitive edge.
Profit After Tax (PAT): The net profit of a company after all expenses, taxes, and interest have been deducted.
Net Interest Income (NII): The difference between the interest income a bank earns from its lending activities and the interest it pays out to depositors.
Net Interest Margins (NIMs): A profitability metric for banks, representing the difference between interest income earned and interest paid out, as a percentage of interest-earning assets.
Basis points (bps): One-hundredth of a percentage point (0.01%). Used for measuring small changes in interest rates or financial percentages.
Asset quality: The assessment of the riskiness of a bank's loans and investments.
Gross Non-Performing Asset (GNPA): Loans on which the interest or installment has remained overdue for 90 days or more.
Net Non-Performing Asset (NNPA): Gross NPAs minus the provision made by the bank for these bad loans.
Management guides: Projections or forecasts provided by a company's leadership regarding future performance.
Loan growth: The increase in the total amount of loans issued by a financial institution over a period.
Return on Asset (RoA): A financial ratio showing how profitable a company is relative to its total assets.
Return on Equity (RoE): A measure of a company's financial performance calculated as net income divided by shareholders' equity.
Holding-company discount: A situation where the market value of a parent company is less than the sum of the market values of its subsidiaries.
Strategic control: The ability to direct and influence the operations and decisions of a company or business unit.
Biologics: Therapeutic products derived from or synthesized by living organisms.
Generics: Off-patent drugs that are equivalent to brand-name drugs in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.
Contract Development and Manufacturing Organisation (CDMO): A company that offers comprehensive services from drug development to manufacturing for pharmaceutical and biotechnology companies.
Operating leverage: The degree to which a company's costs are fixed versus variable. High operating leverage means small changes in sales can lead to large changes in operating income.
Syngene: Refers to Syngene International Limited, a contract research, development, and manufacturing organization.
Minority interest: The portion of a subsidiary's equity that is not owned by the parent company.
Equity issuance: The process by which a company sells new shares of stock to raise capital.
Earnings Per Share (EPS): The portion of a company's profit allocated to each outstanding share of common stock.
Qualified Institutional Placement (QIP): A method by which Indian public companies can raise capital by issuing securities to qualified institutional buyers.
Bridge financing: Short-term financing used until a company secures a more permanent source of funding.
Business prospects: The potential for future success and profitability of a company.
Product launches: The introduction of new products into the market.
Insulin aspart: A rapid-acting insulin analog used to control high blood sugar.
Transitional headwinds: Temporary challenges or difficulties encountered during a period of change or transition.
Muted demand: Lower than expected or sluggish consumer or business demand for products or services.
Deferred purchases: Postponement of buying decisions by consumers or businesses.
Petcoke prices: Prices of petroleum coke, a byproduct of oil refining used as fuel in industries like cement.
INR depreciation: A decrease in the value of the Indian Rupee relative to other currencies.
Incremental cost pressure: Additional costs that gradually increase the overall expenses of a business.
Ebitda (Earnings Before Interest, Tax, Depreciation, and Amortisation): A measure of a company's operating performance before accounting for financing costs, taxes, and non-cash expenses.
Margins: The difference between revenue and costs, expressed as a percentage.
Realizations: The price at which goods or services are sold.
Variable costs: Costs that change in proportion to the production volume.
Profitability: The ability of a business to generate earnings or profit.
Other income: Income generated from sources other than the company's primary business operations.
Favourable tax rate: A lower than average or beneficial tax rate applied to a company's profits.
GST rate benefit: Advantages derived from the Goods and Services Tax system, such as reduced tax burdens or improved input tax credits.
Capacity expansions: Increasing the production or operational capability of a company.
Medium-term growth visibility: The clarity or predictability of a company's growth prospects over the next few years.
Disciplined cost management: Careful and strategic control over business expenses.
Input cost pressures: Increases in the cost of raw materials or components required for production.
Constructive long-term outlook: A positive and optimistic view of a company's prospects for sustained success over an extended period.
Subsystem supplier: A company that provides components or smaller integrated units that form part of a larger system.
Full system solutions provider: A company that offers complete, integrated products or services designed to meet a customer's overall needs.
AESA radars: Active Electronically Scanned Array radars, advanced radar technology offering superior performance.
Uttam radars: Refers to specific indigenous radar systems developed in India.
Meteorological projects: Projects related to the study and forecasting of weather and climate.
Navy repeat orders: Subsequent orders placed by the navy for previously supplied equipment or systems.
Counter-drone systems: Technologies designed to detect, track, and neutralize unmanned aerial vehicles (drones).
Order book: The value of contracts received by a company for work yet to be completed.
Revenue CAGR (Compound Annual Growth Rate): The average annual growth rate of revenue over a specified period, assuming profits were reinvested.
Ebitda margins: Profitability measure showing Ebitda as a percentage of revenue.
PAT CAGR (Compound Annual Growth Rate): The average annual growth rate of Profit After Tax over a specified period.
Ministry of Defence (MoD): The government department responsible for national defense.
Defense Public Sector Undertakings (PSUs): State-owned enterprises involved in defense manufacturing and services.
Wealth Management: Financial advisory services that preserve and grow wealth for clients.
Private businesses: Refers to the private banking or wealth management segment serving high-net-worth individuals.
Asset services: Services related to managing financial assets.
Opex growth (Operating Expenses growth): The increase in a company's day-to-day operational costs.
FY25-28E: Fiscal Year 2025 to 2028 estimates.